TURKU, Finland and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will hold a conference call today to discuss new positive clinical data from the Company's ongoing Phase I/II BEXMAB study. Conference Call and Webcast Wednesday, July 19, 2023, at 8:30 am ET. The live call may be accessed by dialing (877) 407-3982 for callers in the US and (201)
Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Faron Pharmaceuticals Oy
Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress
Bexmarilimab mode of action in AML/MDS supported with durable Clever-1. | June 9, 2023
KH Group Plc - Managers' Transactions streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.